INSITU Oct 2006 - Vol 2 - Institute of Chemical & Engineering ...

MICA(P)290/05/2006 OCT 2006 - VOL 2
A Newsletter of the Institute of Chemical and Engineering Sciences
INSIDE: 2-3 Research Highlights 4 Key Facilities and Infrastructure @ ICES 6 Patents Granted 7 Up-close & Personal 8 Upcoming Events
First Petrochemical R&D Centre to be Set Up in Singapore
by Mitsui Chemicals, Inc.
On 14 August 2006, Mitsui Chemicals, Inc. (MCI), one of the top
global chemicals companies announced the setting up of its
first overseas petrochemical R&D centre in Singapore. This is
the company’s first such establishment outside Japan and it
will be housed at ICES in Jurong Island. The centre is scheduled
to be opened on 1 October 2006.
To formalise this collaboration, a Memorandum of
Understanding (MOU) between the two parties was signed by
Mr Manabu Fujise, Managing Director of Mitsui Chemicals
Singapore Ltd (2nd from right) and Dr Keith Carpenter, Executive
Director, ICES (4th from left).
Named Mitsui Chemicals Singapore Technical Centre, the
research centre will focus on catalysis and asymmetric synthesis
– the two areas where Mitsui Chemicals and ICES have joint
research. Catalysis is a forefront technology that provides the
means to create environmentally friendly and efficient
processes and new materials and chemicals. With fewer steps
needed in the entire chemical process, this translates into
tremendous time-, energy- and cost-savings for chemicals
companies such as Mitsui.
Dr Akihiro Yamaguchi, Senior Managing Director of MCI said,
“Our mid-term business plan will focus on fostering
competitive technology in the Performance Materials sector
and strengthening global competitiveness in the
Petrochemicals & Basic Chemicals sector. We believe Singapore
functions as the business hub of Asia, and will lead MCI to
successfully attain these goals. The Mitsui Chemicals Singapore
Technical Centre, which will include functions ranging from
R&D to production, will greatly contribute to our further
business expansion in Asia.”
Mr Boon Swan Foo, Managing Director of A*STAR, who signed
the first research collaboration agreement with Dr Yamaguchi
in September 2004, remarked, “I am pleased that what
started as a joint collaboration has now translated into an
independent research cum business and production centre.
This is a win-win partnership where innovation in chemical
science technologies will drive the company’s overall
competitiveness, as well as position Singapore as a stronghold
for chemical science R&D. We look forward to furthering the
longstanding relationship we have with MCI.”
“Mitsui’s choice of Singapore as the location of its first
overseas research centre, among the many countries it already
operates in, testifies to the high quality of R&D capabilities and
talents we have here. Its co-location with ICES, for a start, is a
strategic move where ICES’ world-class catalysis capabilities
has been identified as a key factor that can accelerate Mitsui’s
R & D activities in Singapore and in Asia,” said Prof Chong Tow
Chong, Executive Director of the Science & Engineering
Research Council of A*STAR.
The establishment of the R&D centre is the latest in a series
of partnerships between A*STAR and Mitsui. Since September
2004, Mitsui has been working on two successful research
collaborations with ICES to develop novel catalysts and next
generation technologies that will potentially enhance the
process and development of new petrochemical,
pharmaceutical or agrochemical products.
In April 2006, the company partnered A*STAR and the
Singapore Economic Development Board (EDB) to hold its
acclaimed scientific symposium in Singapore and re-named
it Singapore International Symposium 2006 – a sign of the
recognition it has for the Republic’s contribution in chemical
and materials science advancement.
Ms Aw Kah Peng, Director of the Chemicals Cluster at EDB, said,
“In addition to being a strategic manufacturing base for
many leading chemical companies, Singapore is increasingly
becoming a choice location for R&D. The government is
committed to supporting R&D to drive the long-term growth
of the chemical industry.”
Singapore is currently among the top 10 petrochemical hubs
in the world. With strong research capabilities at A*STAR and
the research scientists and engineers being trained at ICES
and the universities, Singapore has increasingly been
attracting foreign investments in R&D of new technologies
and processes.
A research institute of the Agency for Science, Technology and Research (A*STAR)

Research Highlights
Enzymatic Production of Biodiesel
In the face of diminishing petroleum reserves and global
concern over greenhouse gases, the search for an
alternative fuel, which is both renewable and clean,
gathers momentum. Biodiesel (fatty acid methyl ester,
FAME), synthesised from animal fats or vegetable oils (eg.
palm oil), is an ideal candidate, being biodegradable, nontoxic,
and essentially free of sulfur and aromatics. Being
derived from renewable sources means that this fuel has
little net contribution to CO 2 in the atmosphere. In
addition, one major advantage is that biodiesel can be
mixed with petroleum diesel and used directly in existing
diesel engines with few or no modifications.
Beginning with fats or oils, a simple reaction with methanol
is carried out using a catalyst. After removing the glycerol
by-product, biodiesel is obtained. Commercially, a chemical
route is used which employs sodium hydroxide as the
catalyst. However, this process can only use fats/oils which
are free of contaiminating fatty acids, and it is difficult to
recover the glycerol for other uses. The high energy
consumption is also a disadvantage.
An alternative method is to use a biocatalyst eg., lipase
(an enzyme). This alternative route to biodiesel is
environmentally friendly and can be carried out under
mild conditions. Free fatty acids contained in fats or oils
do not present any problem as they can be
simultaneously converted to biodiesel. The glycerol byproduct
is also formed in its natural state and can thus
be easily separated and recovered from the biodiesel,
unlike the chemical route where glycerol is produced in
the salt form. By using lipase, which is immobilised onto
solid support, the catalyst can be easily recycled and
reused. Another advantage is that high value substances
such as vitamin E, present in quantities up to 800-1200
ppm in fresh crude palm oil, can be retained and extracted
through this mild process, whereas it is destroyed in the
high-temperature chemical process. However, enzyme
deactivation and high enzyme cost are major challenges
for the development of an economically competitive
biocatalytic process.
H 2 C OOCR 1
HC OOCR 2
H 2 C OOCR 3
+ CH 3 OH
catalyst
R 1 CO 2 CH 3
R 3 CO 2 CH 3
H 2 C OH
R 2 CO 2 CH 3 + HC OH
H 2 C OH
triglyceride methanol biodiesel glycerol
To overcome the deactivation of enzymes caused by
methanol and glycerol in the biocatalytic route to biodiesel,
our biocatalysis team has invented a two-phase reaction
process which significantly improves the stability and
productivity of enzyme. Within the phase where the
enzyme catalysed reaction takes place, the levels of
methanol and glycerol can be regulated, thus avoiding
enzyme poisoning by these two compounds. This process
allows a commercial immobilised lipase to be reused up
to 8 times with high yields and no significant loss in enzyme
activity, a major improvement over current published data.
Preliminary work at ICES has also been carried out on
Vitamin E extraction, using commercial adsorbents to
recover up to 40% of the Vitamin E in crude palm oil.
Biodiesel Process Flow
Crude Palm Oil
Shaking with methanol
at 180 rpm, 60 o C
HPLC analysis of methyl esters
Although biodiesel is advantageous over fossil diesel in
many aspects, one drawback is its higher cloud point
(temperature where the fuel becomes non-homogenous
or cloudy, making it unsuitable for engine use), which makes
it difficult to use in cold weather (below -5 o C). The existing
method of overcoming this problem is to use additives. An
alternative solution is the so-called second generation
biodiesel, a mixture of parafin and isoparafin, produced by
hydrolysis instead, followed by hydrogenation and
isomerisation steps. ICES is now actively working on further
improvement of the enzymatic process, recovery of saltfree
glycerol, extraction of Vitamin E, and is considering the
production of a second generation biodiesel.
The list of relevant publications and patents is as follows:
Separation of Biodiesel
by centrifugation
Biodiesel (methyl ester of fatty acids)
1. Talukder MMR, Wu JC. A novel process for enzymatic production of
biodiesel by methanolysis of oils or fats. US provisional patent, filed
on 14 November 2004.
2. Talukder MMR, Puah SM, Wu JC, Choi WJ, Chow Y. Lipase-catalyzed
methanolysis of palm oil in presence and absence of organic solvent
for production of biodiesel. Biocatalysis & Biotransformation, 2006, 24:
in press.
2

3
Exploiting Novel Particle Technology for More Effective Inhaled Drug Delivery
Inhaled dry powder aerosols are effective therapeutic
carriers for target-specific treatments of various
pulmonary diseases, such as asthma, cystic fibrosis,
chronic pulmonary infections and lung cancer. Owing
to the high permeability of the human lung’s epithelia
towards therapeutic agents, inhaled dry powder aerosols
can also serve as attractive alternatives to oral and
parenteral routes for the systemic delivery of other
therapeutic agents, such as insulin or growth hormone,
that can only be delivered currently through the
gastrointestinal tract or parenterally by either intravenous
or intramuscular injections.
Due to rapid advances in nanotechnology, the use of
nanoparticulate drugs as therapeutic carriers has become
a subject of very active research. Nanoparticulate drugs
have an enormous potential in significantly improving
the systemic bioavailability of a drug, which is defined
as the rate and extent of the therapeutically active drug
that reaches systemic circulation. The high systemic
bioavailability of nanoparticulate drugs is attributed to
their higher dissolution rate in an aqueous environment,
resulting from the larger surface areas compared to their
micron-sized particle counterparts.
As a result, a wide range of nanoparticulate drugs for oral
and parenteral delivery, in the form of nanoparticulate
suspensions and nanoparticulate composites, has been
investigated, and several of them have already been
commercially manufactured. However, much less
attention has been paid to the dry powder aerosol
delivery of nanoparticulate drugs. The current lack of
commercial appeal in dry powder aerosol delivery of
nanoparticulate drugs is attributed to the fact that: 1)
nanoparticulate aerosols are predominantly exhaled and
not deposited in the lungs due to their extremely low
inertia, and 2) the persistent aggregation problem arising
from their small size, which makes their physical handling
extremely difficult for the dry powder inhaler (DPI)
applications.
To circumvent the above problems, the present work has
involved the development of a novel formulation
technique to manufacture micron-sized carrier particles
designed to facilitate the delivery of nanoparticulate drugs
via inhalation. Large hollow carrier particles (Figure 1),
whose shells are composed of nanoparticulate aggregates
(Figure 2) that can potentially be loaded with therapeutic
agents, have been manufactured by employing a spray
drying technique. The nanoparticulate aggregates are
designed to disassociate into primary nanoparticles in
the aqueous environment of the lungs, where the
Figure 1.
Large hollow
nanoparticulate
aggregates as
carrier particles
Figure 2.
A close-up view of
the shell
composed of the
nanoparticulate
aggregates
therapeutic agents entrapped in the nanoparticles are
released, and subsequently delivered to a specific
pulmonary target, or into systemic circulation. The large
hollow nanoparticulate aggregates have been
manufactured using nanoparticles of differing chemical
nature and size. Owing to their physical characteristics,
the large hollow nanoparticulate aggregates possess two
valuable attributes for use in a dry powder inhaler: 1) the
large geometric size (d g 10µm) reduces their tendency
to aggregate, which consequently improves the
flowability of the carrier particles from the inhaler, and
2) by virtue of their small aerodynamic diameters
(d a 5µm) , the deposition of the carrier particles in the
mouth and throat regions is minimised, so that they are
capable of reaching the targeted alveolar region of the
lungs more effectively.
Reference
Hadinoto K., Phanapavudhikul P., Zhu K.W and Tan R.B.H., Novel
formulation of large hollow nanoparticulate aggregates as potential
carriers of inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem.
Research 45, 3697 - 3706 (2006).

Key Facilities and Infrastructure @ ICES
Catalyst Development and Testing
A) Catalyst developing and testing units
A variety of fixed-bed and batch reactors are available for
screening and evaluation of catalysts. The fixed-bed reactors
are typically equipped with online analysis and mostly used
to evaluate heterogeneous catalysts in continuous
petrochemical processes. The batch reactors are more
versatile and can be used to evaluate all types of catalysts
for the production of both chemicals and polymers.
Computer controlled catalyst unit at the high pressure bay
B) Explosion proof experimental bays
This facility consists of 4 cubicles for conducting both
small and pilot-scale reactions under high pressure.
Currently, 3 automated high-pressure fixed-bed reactors
are available for catalyst evaluation and process
development related to natural gas conversions.
C) High throughput catalyst preparation and testing
i) High throughput screening system for heterogenous
catalysts – This automated system has a catalyst
preparation unit capable of preparing 60 catalysts in
parallel and a fixed-bed reactor capable of testing 5
catalysts simultaneously.
ii) HTS work station for biocatalysts – This automated
work station can provide a ten-fold increase in the
efficiency of screening and genetic modification of
biocatalysts. It can also be used to isolate target
microorganism from natural soil samples to be employed
as biocatalysts.
iii) AMTEC-16 slurry reactor system – This high pressure
reactor system is capable of running 16 reactions
simultaneously with independent T and P controls for
each reactor. It can be used to screen catalysts, optimise
reaction conditions, and measure kinetics.
Process Control and Optimisation
A) Process simulation and optimisation
Advanced process control tools that enable
chemical plants to overcome alarm problems
and optimally manage process transition/grade
change.
B) Process control demonstration room
This model of next-generation control room
seamlessly integrates process measurement,
distributed control system, real-time plant floor
video, real-time dynamic process simulation,
and abnormal event detection and diagnostics
to enable plant operators make quick
operational decisions.
Process control and optimisation
4

5
Crystallisation and Formulation Facilities Development
and
Infrastructure
in-situ crystallisation monitoring & control
Applications
A) In-situ crystallisation monitoring and control facilities
In-situ crystallisation facilities have been set up to develop
and optimise crystallisation processes to obtain crystal
products with desired properties. The facilities also help in
advancing fundamental understanding of crystal growth
and nucleation phenomena.
B) Formulation science laboratory
This laboratory is set up to develop scientific understanding
of how particle properties affect formulability and
bioavailability. These tools are also useful for the design
of novel formulation techniques and to optimise existing
manufacturing processes for the pharmaceutical, specialty
chemicals, food & beverages industries.
C) Milling and granulation laboratory
The laboratory addresses the needs of secondary
pharmaceutical manufacture as well as industries that
require general solid processing.
Reaction Engineering, Reactor Development
A) In-situ reaction monitoring laboratory
To study synthetic organic reactions for the fine chemical
and pharmaceutical industries using state-of-the-art leading
edge spectrometers and physical property measurement,
all on-line and in-situ. The available techniques include
Raman optical activity for real time
enantiomer determination, Mid-Infrared
(MIR), Far-Infrared (FIR), Fourier Transform
Infrared (FTIR), Raman, supported by
novel chemometrics software.
B) Reaction calorimetry
The reaction calorimetry facility is
designed to study thermal events
involved in reactions and processing of
solids, to enable the design of cooling
and safety protection systems for pilot
scale and full scale operation.
C) Mixing and scale up laboratory
The mixing laboratory is equipped with tools necessary to
study the effects of mixing and fluid dynamics on reactions
and processes when scaling up.
On-line reaction monitoring set up (FIR and MIR)

Patents Granted
The following are ICES’ first 2 patents that have been granted.
Title of Invention: Poly (aralkyl ketone)s and Methods of
Preparing the Same
US Patent Number: US 7,034,187 B2
Inventor: Anbanandam Parthiban
About the Invention
Polymers containing the keto functional group have wide
applications as engineering thermoplastics, plasticisers,
fillers and polymer additives. To date, two classes of
polymers containing keto groups are known, viz. aromatic
polyketones (I) (which also includes polyether ketones)
and aliphatic polyketones (II). This invention is concerned
with the development of a new class of polymer containing
keto functional groups, broadly termed as poly (aralkyl
ketone)s (III).
This polymer consists of methylene and keto groups
flanked between phenylene units. Such polymeric
structures can be considered as backbone functional
polymers. The methylene group of such a polymer is
activated both by the carbonyl group as well as the
phenylene moiety while the carbonyl group in this class
of polymers is a potential electrophilic site. This clearly
highlights the potential of this class of polymers for further
functionalisation.
Title of Invention: Carborane Trianion Based Catalyst
US Patent Number: US 7,053,158 B2
Inventor: Zhu Yinghuai
About the Invention
Ziegler-Natta catalyst is used extensively for the
polymerisation of simple olefins to obtain a desired
molecular weight (e.g. ethylene, propene and 1-butene)
and is the focus of much academic attention. However,
most of the known Ziegler-Natta catalyst systems fail to
polymerise functionalised olefins (e.g. halogenated olefins)
because the early transition metal centers in these catalysts
are highly electrophilic, which generally makes it impossible
to use olefins containing polar functional groups as
monomers or co-monomers. Therefore conventional free
radical polymerisation is the current technique used by the
polymer industry to produce a wide range of functionalised
polymers (e.g. polyvinylacetate, polyvinylchloride,
polytetrafluoroethylene, etc.), but the mechanistic
implications of the free radical method make it unsuitable
for the preparation of predetermined polymer architectures
with precise and narrow molecular weight distributions.
This invention relates to the geometry-constrained trianion
metallocarborane compounds, which are active as Ziegler-
Natta catalysts for the polymerisation of functionalised
olefins and therefore are able to be used as alternative
catalysts to prepare functionalised polymers or copolymers,
especially for those which have desired structure
and molecular weight distributions.
ICES/IMRE/Mitsui Chemicals – Technical Meeting
by Dr Selvasothi Selvaratnam
In May 2006, a team of researchers from ICES and IMRE
travelled to Chiba, Japan for a technical meeting with
their collaborators on three projects (two with ICES and
one with IMRE) that were initiated in 2004 when A-STAR
signed a collaborative research agreement with Mitsui
Chemicals Inc.
6
The collaboration between Mitsui and ICES is conducted
by the New Synthesis Techniques and Applications (NSTA)
and Applied Catalysis (AC) research groups. They are
working on developing effective catalysts for asymmetric
C-C bond forming reactions and BTX production,
respectively. IMRE and Mitsui are leveraging on each other’s
capabilities to develop nano-structured materials using
functionalised silsesquioxane and exfoliated clay.
Research staff involved in this meeting included Drs Keith
Carpenter, PK Wong, Christina Chai, Marc Garland, Fethi,
(Left to right) Dr Yamaguchi, Dr Carpenter, Prof Chua, Dr Wong
Selva, Liu Yan, Wee Chuan, Li Chuanzhao, He-Chaobin, Alan
Selinger and Prof Chua Soo Jin.
During the two days of intense discussions at the Sodegaura
Research Center, the latest project developments were

7
highlighted and fruitful ideas exchanged. The technical
teams then presented a summary of the discussions to
the steering committee comprising Dr Carpenter, Prof
Chua, Dr Fujita and Dr Honjyo.
On the last day, the Singapore team was invited to a dinner
Research team from NSTA in discussion with their Mitsui counterpart during the
technical meeting
hosted by Dr AkihiroYamaguchi, Senior Managing Director
of Mitsui Chemicals Inc., at the Mitsui Club House. We were
served sumptuous French-Japanese cuisine, prepared by
their in-house chefs.
Following the technical meetings, several milestones were
identified for the ICES project members to work on. In the
BTX project, effort will be made to improve the activity of
conventional and new catalysts. This includes carrying out
in-situ spectroscopic studies to obtain information about
reactions intermediates and the nature of the catalysts
during the reaction.
The Asymmetric Synthesis project members will be
looking into enhancing the enantioselectivities of selected
C-C bond forming transformations by designing new
catalytic systems.
Up-close & Personal with Alvin Hung, our A*STAR Scholar
Alvin Hung has become a familiar and
friendly face at ICES over the past ten
months. This energetic A*STAR scholar will
shortly leave Singapore to do a Ph.D. in
Organic Chemistry at Cambridge University.
The Editorial team conducted an interview
with him and wish to share some of his
thoughts and experience with you.
Tell us about yourself. I was born and bred in Singapore.
I completed my ‘A’ levels in 1999 at National Junior
College. After being selected as an A*STAR scholar, I spent
some time working at ICES looking at the crystallisation
of paracetamol (commonly known as “panadol”) under
the mentorship of Dr Ann Chow. After this short stint at
ICES, I went to the United States to do a Bachelor of
Chemical Engineering degree at the University of
Wisconsin in Madison. I returned to ICES during a summer
break and again after I graduated, where I spent a year
working with Dr Felicity Moore, Dr Paul Bernardo and Ms
Xu Jin from the NSTA programme.
What projects have you been involved with at ICES
recently? My work at NSTA involved the synthesis of small
molecule inhibitors of the protein Bcl-X L , a regulator for
apoptosis (programmed cell death). This is a collaborative
project with Dr Henry Mok from the National University
of Singapore (NUS) and Dr Victor Yu from the Institute of
Molecular and Cell Biology (IMCB). Besides doing synthesis,
computational studies were also conducted with the help
of Dr Mok to calculate the binding energies of various
small molecules to a particular protein, and correlating
this affinity with what we learnt from actual biological
studies that were done by Dr Victor Yu.
What was the most important thing you learnt during
your time here at ICES? I have always been a very practical
and result-oriented person. The past ten months at ICES
have led me to discover something about the nature of
research – that it is sometimes better to work slowly and
patiently than to rush for results.
Why the change to Organic Chemistry? Although in
school, I always performed better in maths and physics
related subjects but organic chemistry has always been
my first love and that is what I will pursue for my
postgraduate studies.
How has your background in Chemical Engineering
influenced your perspective on synthetic chemistry during
your attachment? To be frank, during my attachment, I
have been simply concentrating on learning the practical
and theoretical aspects of organic chemistry. Not much
chemical engineering knowledge has been applied to the
synthetic work that I have been doing all this while. But I
am very sure that the fusion of both areas of knowledge
will benefit me tremendously in the future.
Tell us about your postgraduate project. I will be working
with Professor Chris Abell at Cambridge University
investigating small molecules for protein inhibition. In fact,
the project is similar to what I have been involved with at
ICES. I should be well prepared!
Last words before you leave ICES for your studies. I want
to thank my mentor Dr Chai (Programme Manager, NSTA),
who has contributed so much to my learning at ICES. Despite
her busy schedule, she always found time to tutor me. I am
going to miss her “mini lectures” and “whiteboard tests” when
I leave. And also big hugs to both Dr Felicity Moore and Dr
Paul Bernardo. Felicity has always been ever so patient and
detailed in teaching me chemistry. And Paul, thanks for the
witty ideas on the project. I am not going to miss out
thanking Kok Peng! I enjoyed exchanging mechanistic
questions with you in the lab. Finally, thanks to all who have
made my stay in ICES a fruitful and memorable one!

Our Scientific ‘Brainpowers’ (Updated)
Scientific Advisory Board (SAB), comprises leading industrialists
and academics, with a global view, providing advice on overall strategy
and direction for ICES’ research programmes.
Professor J.W. (Hans) Niemantsverdriet
(Chairman)
Dean, Department of Chemical Engineering
and Chemistry, Eindhoven University of
Technology
Professor William R Schowalter
Class of 1950 Professor in Engineering
and Applied Science Emeritus,
Princeton University
Dr Jens Rostrup-Nielsen
Director Special Projects,
Company Management,
Haldor Topsoe A/S, Denmark
Professor Michael Shuler
Department of Biomedical Engineering
and School of Chemical and Biomolecular
Engineering, Cornell University
Professor John Garside
Emeritus Professor, School of Chemical
Engineering and Analytical Sciences,
University of Manchester
Professor Ignacio Grossmann
Director, Center for Advanced Process
Decision-making, R.R. Dean University
Professor Department of Chemical
Engineering, Carnegie Mellon University
Professor Ng Ka Ming
Chair Professor, Department of Chemical
Engineering, Hong Kong University of Science
and Technology. CEO, Nano and Advanced
Materials Institute Ltd
Mr John Mitchell
Formerly Senior Vice President, Pfizer Inc.
Formerly President, Pfizer Global
Manufacturing Division
Editorial Board
Advisor
Dr Keith Carpenter
Chief Editor
Dr Manjeet Singh
Members
Ms Winnie Chan
Ms Fong Wai San
Dr Felicity Moore
Dr Ang Thiam Peng
Mr Vivek Kumra
Ms Wan Nur Hanani Bte Rohman
Ms Josephine Keng
Ms Surene Ho
Mr Tsai Yih Wen
Ms Hera Adam
Senior Advisors, comprise selected world leading academics and
industrialists who are leaders in their specialised field of expertise
which are important to ICES, providing consultancy and advice on
ongoing project progress and directions.
Professor Frits Dautzenberg
Formerly Vice President at ABB Lummus,
appointed September 2002 for Applied Catalysis
Professor Brian Cox
AstraZeneca Global Process Research and
Development, appointed June 2003 for NSTA
Professor Eite Drent
Leiden Institute of Chemistry, appointed
May 2006 for Applied Catalysis
Professor Richard Taylor
University of York, appointed
April 2006 for NSTA
Upcoming Events
Oct – Dec 2006
When Name of Event Venue Brief Description
9 Oct Opening Ceremony of ICES, Singapore Opening Ceremony
Mitsui Chemicals Singapore
Technical Centre
12-13 Oct Symposium: “Exploiting Biopolis, Singapore Formulation
Emerging Formulation
Sciences
Sciences Technologies for
Symposium
Pharmaceutical & Fine
Chemicals Manufacturing”
1-3 Nov ICES SAB meeting Singapore Meeting
6 - 8 Dec 4th Asia Pacific Congress on Singapore Symposium
Catalysis (APCAT 4)
17-21 Dec 9th International Symposium for Grand Copthorne Symposium
Chinese Organic Chemists (ISCOC-9) Waterfront Hotel,
6th International Symposium for Singapore
Chinese Inorganic Chemists (ISCIC-6)
When Visiting Professor Research Group
2 Oct Professor Peter Kundig, University of Geneva, Switzerland NSTA
12-13 Oct Professor John Dodds, Ecole des Mines d’Albi, France CPS
12-13 Oct Professor Hans Junginger, Naresuan University, Thailand CPS
12-13 Oct Dr Gerry Steele, AstraZeneca, UK CPS
12-13 Oct Dr Simon Black, AstraZeneca, UK CPS
Institute of Chemical and
Engineering Sciences
1 Pesek Road, Jurong Island
Singapore 627833
Tel: +65 6796 3700
Fax: +65 6873 4805
www.ices.a-star.edu.sg
For enquiries, please contact:
insitu@ices.a-star.edu.sg
31 Oct Professor John Garside, University of Manchester, UK CPS
20-24 Nov Professor Richard Taylor, University of York, UK NSTA
4-5 Dec Professor Roger Sheldon, TU Delft, The Netherlands AC
Dr Ulf Hanefeld, TU Delft, The Netherlands
Professor Ikuo Fujii, Osaka Prefecture University, Japan
4-10 Dec Professor D.W. Goodman, Texas A&M, USA AC
15 Dec Professor Heinrich Vahrenkamp, NSTA
University of Freiburg, Germany
in situ is published by the Insitute of Chemical and
Engineering Sciences (ICES).
Reproduction of material in this publication without written
permission from ICES is prohibited.
Printed & Designed by Octogram Press Pte Ltd